Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction By Investing.com

Transaction: (JO:) Expected to close in the coming days

SOMERSET, NJ & COPENHAGEN, Denmark–( BUSINESS WIRE )–Catalent, Inc. (Catalent (NYSE: ), NYSE: CTLT ), a leader in developing and delivering better treatments for patients worldwide, and Novo Holdings A. /S (Novo Holdings), a global life sciences investment company, announced today that the companies have entered into a regulatory closing all conditions. for their pending deal.The companies now expect to close the deal in the coming days.

Today marks an important step in our transition to private ownership under Novo Holdings, a leading life sciences investment company, said Catalent President and CEO Alessandro Maselli.As we approach the completion of the transaction, I want to thank Catalent team for their hard work and share my enthusiasm for the bright future of our company. With Novo Holdings’ support and access to additional resources, Catalent will be well positioned to drive innovation and expand its offerings to benefit customers and the patients they serve, ultimately accelerating our strategy to create value for stakeholders.

We are pleased to have reached this latest milestone, which we believe reflects the significant benefits the proposed transaction is expected to bring, said Jonathan Levy, Senior Partner at Novo Holdings.We are excited for the Catalent team as we approach in partnership with and support in its mission to advance healthcare innovation and improve patient outcomes.

For more information regarding the transaction, visit transaction.catalent.com.

Advisors
Citi and JP Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Catalent and Jones Day served as legal advisor to Catalent’s board of directors. : Morgan Stanley & Co (NYSE:). LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP served as legal advisor to Novo Holdings. Arnold & Porter Kaye Scholer LLP served as legal advisors to Novo Nordisk (NYSE:).

About Novo Holdings A/S
Novo Holdings is the holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. Novo Holdings aims to improve the health of people and the sustainability of society and the planet by generating attractive long-term returns from the assets of the Novo Nordisk Foundation.

Novo Holdings, wholly owned by the Novo Nordisk Foundation, is the controlling shareholder of Novo Nordisk A/S (formerly Novozymes (OTC:) A/S) and manages an investment portfolio with a long-term return perspective. In addition to stocks, bonds, From managing a broad portfolio of real estate, infrastructure and private equity assets, Novo Holdings is a leading global life sciences investor in its Seed, Venture, Growth, Asia, Planetary Health and Principal Through the Investments teams, Novo Holdings invests in life science companies at all stages of development. As of the end of 2023, Novo Holdings had total assets of 149 billion. www.novoholdings.dk

About Catalent, Inc
Catalent, Inc. (NYSE: CTLT), is a global leader in enabling pharmaceutical, biotech and consumer healthcare partners to optimize product development, launch and lifecycle delivery for patients worldwide in developmental sciences, delivery technologies and multimodal manufacturing With broad and deep industry scale and expertise, Catalent is the industry’s preferred partner for personalized medicines, consumer health brand extensions and blockbuster medicines more than 1,500 partner development projects and launch more than 150 new products each year. Its flexible manufacturing platforms deliver approximately 70 billion units of approximately 8,000 products annually. Catalent’s workforce of approximately 17,000 includes more more than 3,000 scientists and technicians.Headquarters in Somerset, New Jersey Revenue of approximately $4.4 billion in fiscal 2024. For more information, visit www.catalent.com.

Forward-looking statements
This press release and any related oral statements may include both historical and forward-looking statements and guidance.All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of the Securities Act of 1933. within the meaning of Section 27A, as amended, and Section 21E of the Securities Exchange Act of 1934; modified. These forward-looking statements generally can be identified by the use of statements that include expressions such as: believe, expect, predict, intend, estimate, plan, anticipate, anticipate, hope, predict, likely, may, could , target, want , or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s goals, plans or objectives are or may be forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or unknown or uncertainties materialize, actual results could differ materially from Catalent’s expectations, projections and guidance.Certain factors that could cause actual results to differ materially differ from forward-looking statements, including, but not limited to, the pending merger of Catalent with an affiliate of Novo Holdings (the Merger), the completion of the Merger on the expected terms and timing, including the receipt of antitrust and other regulatory approvals and clearances, the satisfaction of other conditions to the completion of the Merger; potential litigation in connection with the merger that Catalent, Novo Holdings or their respective affiliates, directors or by or against officials, including the consequences of any outcome related thereto, the risk that disruptions from the Merger will harm Catalent’s relationships, and certain restrictions on the reliance on the Merger that may affect Catalent’s ability to pursue attractive business opportunities or strategic transactions.

These forward-looking statements speak only as of the date of this press release or their preparation, and Catalent undertakes no obligation, and specifically disclaims any obligation, to publicly release the results of these forward-looking updates or revisions. statements that may be made to reflect future events or circumstances after the date of such statements or to reflect expected or unanticipated events.

View the source version at businesswire.com. https://www.businesswire.com/news/home/20241213700784/hy/

Catalent
Investor:
Paul Surdez
+1 (732) 537-6325
investors@catalent.com

Media:
Laura Hortas
+1 (609) 240-7025
media@catalent.com:

Novo Holdings
(Global Inquiries) Marie-Louise Jersey, Senior Communications Associate
(US Polls) Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk:

Source: Catalent, Inc.